Perioperative management of anticoagulated patients undergoing repeated intravitreal injections [4]

Archives of Ophthalmology

Volumn 125, Issue 7, 2007, Pages 994-

  Meyer, Carsten H ^a   Callizo, Josep ^b   Mennel, Stefan ^b   Kussin, Andrea ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; HUMAN; INCIDENCE; LETTER; MAINTENANCE THERAPY; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK REDUCTION; THERAPY EFFECT;

EID: 34447508439     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.7.994     Document Type: Letter

References (5)

1. Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol. 2006;124(11):1558- 1565.
2. Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698.
3. Hewitt RL, Chun KL, Flint LM. Current clinical concepts in perioperative anticoagulation. Am Surg. 1999;65(3):270-273.
4. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-1349.
5. Ziemssen F, Bartz-Schmidt KU, Grisanti S. (Side) effects of VEGF inhibition [in German]. Ophthalmologe. 2006;103(6):484-489.